COMPLETE RESPONSE OF CUTANEOUS METASTASIS IN A MELANOMA PATIENT TREATED WITH IPILIMUMAB

We present the case of a 58 year old woman, who achieved complete response for her cutaneous melanoma metastasis after treatment with ipilimumab at 3 mg/Kg. The patient was given dacarbazine as a first line treatment for her cutaneous metastasis and a partial response was achieved. However, after 26 cycles of chemotherapy, the cutaneous lesions progressed, so ipilimumab was chosen as a second line treatment. The patient was eligible for the compassionate use of ipilimumab.Two weeks after the fourth cycle with ipilimumab, a complete response of most cutaneous metastasis was noted, with a partial response of the remaining lesions, which were still regressing at the last follow-up visit. Ipilimumab, which was recently reported to improve survival in patients with metastatic melanoma, represents a most promising immunotherapeutic drug and it has been approved for patients with advanced melanoma as a first- and second-line treatment by the FDA and as a second-line treatment by the European Medicines Agency (EMA).